Zynyz
Zynyz ingredients
| Active ingredient | Strength |
|---|---|
| Retifanlimab | 25 mg/mL |
What Zynyz is used for
The FDA lists the approved uses on the official label (below). In the EU, retifanlimab is approved as Zynyz for:
Squamous cell carcinoma of the anal canal (SCAC) Zynyz is indicated in combination with carboplatin and paclitaxel for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). Merkel cell carcinoma (MCC) Zynyz is indicated as monotherapy for the first line treatment of adult patients with metastatic or recurrent locally advanced Merkel cell carcinoma (MCC) not amenable to curative surgery or radiation therapy.
EU wording from the European Medicines Agency; US approved uses can differ.
Key facts
- Brand
- Zynyz
- Generic name
- Retifanlimab-dlwr
- Made by
- Incyte Corporation
- Forms
- Injection
- Given
- Intravenous
- Drug class
- Programmed Death Receptor-1 Blocking Antibody
- FDA approval
- Biologic licence (BLA) BLA761334
- On the US market since
- 2023
Official information
- MedlinePlus drug information (search for Retifanlimab-dlwr)
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Zynyz?
Zynyz (Retifanlimab-dlwr) is a cancer medicine made by Incyte Corporation, approved by the US FDA.
What are the ingredients of Zynyz?
Zynyz contains Retifanlimab (25 mg/mL).
Is Zynyz approved in Europe?
The same active substance is approved in the EU as Zynyz.
From the FDA National Drug Code directory (open.fda.gov, public domain) and the European Medicines Agency medicines list. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, USA